Belagenpumatucel-L for the treatment of non-small cell lung cancer

Erika Rijavec, Federica Biello, Carlo Genova, Giulia Barletta, Claudia Maggioni, Maria Giovanna Dal Bello, Simona Coco, Anna Truini, Irene Vanni, Angela Alama, Sabrina Beltramini, Maria Attilia Grassi, Francesco Boccardo, Francesco Grossi

Research output: Contribution to journalArticle

Abstract

Introduction: Immunotherapy has become a promising approach for the treatment of NSCLC. In order to stimulate the host immune system against tumour antigens, several cancer vaccines have been generated and evaluated. Belagenpumatucel-L is a whole tumour cell vaccine expressing the antisense strand of the TGF-β2 gene.Areas covered: The purpose of this article is to review the most relevant findings of clinical trials testing belagenpumatucel-L in advanced NSCLC patients.Expert opinion: Although the Phase III trial investigating belagenpumatucel-L in stage III/IV patients did not meet its primary end point, a survival benefit was observed in several subgroups of patients. Further studies are needed in order to select patients who may benefit from this vaccine.

Original languageEnglish
Pages (from-to)1371-1379
Number of pages9
JournalExpert Opinion on Biological Therapy
Volume15
Issue number9
DOIs
Publication statusPublished - Sep 2 2015

Fingerprint

Non-Small Cell Lung Carcinoma
Cells
Cancer Vaccines
Vaccines
Immune system
Neoplasm Antigens
Tumors
Expert Testimony
Therapeutics
Genes
Immunotherapy
Immune System
Clinical Trials
Testing
Survival
belagenpumatucel L

Keywords

  • Belagenpumatucel-L
  • NSCLC
  • TGF-b2
  • vaccines

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Belagenpumatucel-L for the treatment of non-small cell lung cancer. / Rijavec, Erika; Biello, Federica; Genova, Carlo; Barletta, Giulia; Maggioni, Claudia; Dal Bello, Maria Giovanna; Coco, Simona; Truini, Anna; Vanni, Irene; Alama, Angela; Beltramini, Sabrina; Grassi, Maria Attilia; Boccardo, Francesco; Grossi, Francesco.

In: Expert Opinion on Biological Therapy, Vol. 15, No. 9, 02.09.2015, p. 1371-1379.

Research output: Contribution to journalArticle

Rijavec, E, Biello, F, Genova, C, Barletta, G, Maggioni, C, Dal Bello, MG, Coco, S, Truini, A, Vanni, I, Alama, A, Beltramini, S, Grassi, MA, Boccardo, F & Grossi, F 2015, 'Belagenpumatucel-L for the treatment of non-small cell lung cancer', Expert Opinion on Biological Therapy, vol. 15, no. 9, pp. 1371-1379. https://doi.org/10.1517/14712598.2015.1073709
Rijavec, Erika ; Biello, Federica ; Genova, Carlo ; Barletta, Giulia ; Maggioni, Claudia ; Dal Bello, Maria Giovanna ; Coco, Simona ; Truini, Anna ; Vanni, Irene ; Alama, Angela ; Beltramini, Sabrina ; Grassi, Maria Attilia ; Boccardo, Francesco ; Grossi, Francesco. / Belagenpumatucel-L for the treatment of non-small cell lung cancer. In: Expert Opinion on Biological Therapy. 2015 ; Vol. 15, No. 9. pp. 1371-1379.
@article{154dadcd8415423a8f2ebc93e0879451,
title = "Belagenpumatucel-L for the treatment of non-small cell lung cancer",
abstract = "Introduction: Immunotherapy has become a promising approach for the treatment of NSCLC. In order to stimulate the host immune system against tumour antigens, several cancer vaccines have been generated and evaluated. Belagenpumatucel-L is a whole tumour cell vaccine expressing the antisense strand of the TGF-β2 gene.Areas covered: The purpose of this article is to review the most relevant findings of clinical trials testing belagenpumatucel-L in advanced NSCLC patients.Expert opinion: Although the Phase III trial investigating belagenpumatucel-L in stage III/IV patients did not meet its primary end point, a survival benefit was observed in several subgroups of patients. Further studies are needed in order to select patients who may benefit from this vaccine.",
keywords = "Belagenpumatucel-L, NSCLC, TGF-b2, vaccines",
author = "Erika Rijavec and Federica Biello and Carlo Genova and Giulia Barletta and Claudia Maggioni and {Dal Bello}, {Maria Giovanna} and Simona Coco and Anna Truini and Irene Vanni and Angela Alama and Sabrina Beltramini and Grassi, {Maria Attilia} and Francesco Boccardo and Francesco Grossi",
year = "2015",
month = "9",
day = "2",
doi = "10.1517/14712598.2015.1073709",
language = "English",
volume = "15",
pages = "1371--1379",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "9",

}

TY - JOUR

T1 - Belagenpumatucel-L for the treatment of non-small cell lung cancer

AU - Rijavec, Erika

AU - Biello, Federica

AU - Genova, Carlo

AU - Barletta, Giulia

AU - Maggioni, Claudia

AU - Dal Bello, Maria Giovanna

AU - Coco, Simona

AU - Truini, Anna

AU - Vanni, Irene

AU - Alama, Angela

AU - Beltramini, Sabrina

AU - Grassi, Maria Attilia

AU - Boccardo, Francesco

AU - Grossi, Francesco

PY - 2015/9/2

Y1 - 2015/9/2

N2 - Introduction: Immunotherapy has become a promising approach for the treatment of NSCLC. In order to stimulate the host immune system against tumour antigens, several cancer vaccines have been generated and evaluated. Belagenpumatucel-L is a whole tumour cell vaccine expressing the antisense strand of the TGF-β2 gene.Areas covered: The purpose of this article is to review the most relevant findings of clinical trials testing belagenpumatucel-L in advanced NSCLC patients.Expert opinion: Although the Phase III trial investigating belagenpumatucel-L in stage III/IV patients did not meet its primary end point, a survival benefit was observed in several subgroups of patients. Further studies are needed in order to select patients who may benefit from this vaccine.

AB - Introduction: Immunotherapy has become a promising approach for the treatment of NSCLC. In order to stimulate the host immune system against tumour antigens, several cancer vaccines have been generated and evaluated. Belagenpumatucel-L is a whole tumour cell vaccine expressing the antisense strand of the TGF-β2 gene.Areas covered: The purpose of this article is to review the most relevant findings of clinical trials testing belagenpumatucel-L in advanced NSCLC patients.Expert opinion: Although the Phase III trial investigating belagenpumatucel-L in stage III/IV patients did not meet its primary end point, a survival benefit was observed in several subgroups of patients. Further studies are needed in order to select patients who may benefit from this vaccine.

KW - Belagenpumatucel-L

KW - NSCLC

KW - TGF-b2

KW - vaccines

UR - http://www.scopus.com/inward/record.url?scp=84938967064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938967064&partnerID=8YFLogxK

U2 - 10.1517/14712598.2015.1073709

DO - 10.1517/14712598.2015.1073709

M3 - Article

C2 - 26211534

AN - SCOPUS:84938967064

VL - 15

SP - 1371

EP - 1379

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 9

ER -